Tempus AI Achieves Record Contract Value Exceeding $1.1 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 Jan 26
Source: Businesswire
Tempus AI's stock surged by 11.36% in pre-market trading, crossing above its 5-day SMA, reflecting strong investor interest.
The company announced that it achieved a record total contract value exceeding $1.1 billion as of December 31, 2025, driven by agreements with over 70 pharmaceutical companies, including Pfizer and AstraZeneca. This robust growth in precision medicine positions Tempus for future revenue increases, with a net revenue retention rate of approximately 126% indicating strong customer relationships.
This milestone not only showcases Tempus's expanding influence in the biopharma sector but also enhances its market share, suggesting a positive outlook for the company's growth trajectory in the coming years.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 90.64 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 69.260
Low
80.00
Averages
90.64
High
105.00
Current: 69.260
Low
80.00
Averages
90.64
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
